Sapience Therapeutics has received ODD from the US FDA for its lead programme, ST101, to treat advanced melanoma for patients in stages IIB through IV.
/PRNewswire/ Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of small protein therapeutics to.